Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NuVasive, Inc.
  6. News
  7. Summary
    NUVA   US6707041058

NUVASIVE, INC.

(NUVA)
  Report
Delayed Quote. Delayed Nasdaq - 01/21 04:00:00 pm
57.79 USD   +2.12%
01/12NuVasive Seeks Acquisitions
CI
01/12NUVASIVE INC : Regulation FD Disclosure (form 8-K)
AQ
01/10NUVASIVE : J.P. Morgan 40th Annual Healthcare Conference
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NuVasive Shares Halted, Globus Reportedly Makes Early Takeover Approach

11/15/2021 | 12:54pm EST


ę MT Newswires 2021
All news about NUVASIVE, INC.
01/12NuVasive Seeks Acquisitions
CI
01/12NUVASIVE INC : Regulation FD Disclosure (form 8-K)
AQ
01/10NUVASIVE : J.P. Morgan 40th Annual Healthcare Conference
PU
01/05NuVasive Gets US FDA 510(k) Clearance for Expanded Indications of Use for Attrax Putty
MT
01/05NuVasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with C..
PR
01/05Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with T..
CI
2021NuVasive to Participate in 40th Annual J.P. Morgan Healthcare Conference
PR
2021Truist Securities Adjusts Price Target on NuVasive to $60 From $75, Maintains Buy Ratin..
MT
2021RBC Initiates NuVasive at Outperform With $60 Price Target, Noting 'Material Backlog, N..
MT
2021NuVasive to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
PR
More news
Analyst Recommendations on NUVASIVE, INC.
More recommendations
Financials (USD)
Sales 2021 1 136 M - -
Net income 2021 -15,5 M - -
Net Debt 2021 658 M - -
P/E ratio 2021 -151x
Yield 2021 -
Capitalization 2 990 M 2 990 M -
EV / Sales 2021 3,21x
EV / Sales 2022 2,90x
Nbr of Employees 2 700
Free-Float 88,0%
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | NUVA | US6707041058 | MarketScreener
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 57,79 $
Average target price 64,40 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
J. Christopher Barry Chief Executive Officer & Director
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Daniel J. Wolterman Chairman
Kyle Malone VP-Clinical, Medical & Regulatory Affairs
Aviva McPherron Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NUVASIVE, INC.7.83%2 990
ABBOTT LABORATORIES-10.59%215 794
MEDTRONIC PLC2.57%141 985
BECTON, DICKINSON AND COMPANY5.23%75 431
HOYA CORPORATION-11.34%49 186
BAXTER INTERNATIONAL INC.0.51%43 200